m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00027)
Regulator Name RNA binding protein X (RBMX)
Synonyms
RNA-binding motif protein, X chromosome, Glycoprotein p43; Heterogeneous nuclear ribonucleoprotein G; hnRNP G; HNRPG; RBMXP1
    Click to Show/Hide
Gene Name RBMX
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Beta-catenin (CTNNB1)
Recombinant human endostatin [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for Recombinant human endostatin. The RNA binding protein X (RBMX) has potential in affecting the response of Recombinant human endostatin through regulating the expression of Beta-catenin (CTNNB1). [1], [2]
C 82 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for C 82. The RNA binding protein X (RBMX) has potential in affecting the response of C 82 through regulating the expression of Beta-catenin (CTNNB1). [1], [3]
CEQ-508 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The RNA binding protein X (RBMX) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [1], [4]
References
Ref 1 N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063. doi: 10.1093/nar/gkx141.
Ref 2 Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. doi: 10.1038/s41467-019-11918-y.
Ref 3 Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/Beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. doi: 10.1371/journal.pone.0107463. eCollection 2014.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)